Company Operations by Product

3 Months Ended

Mar. 31, 2019

The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the interim CEO. The interim CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

The following table presents a summary of total revenues by these products:



	Three Months Ended March 31,
Revenues by Product:	2019		2018

Bloxiverz	$	2,568	$	7,491
Vazculep	9,473		12,961
Akovaz	3,792		10,217
Other	604		2,492
Total product sales	16,437		33,161
License revenue	—		132
Total revenues	$	16,437	$	33,293